NCCAM stakeholder meetingNSF GMP program
This article was originally published in The Tan Sheet
Executive SummaryDr. Ruth L. Kirschstein, acting director at NIH's National Center for Complementary and Alternative Medicine, will host a stakeholder dialogue June 20 to discuss NCCAM's "activities and priorities," the center announces in a May 31 e-mail update. NCCAM says meeting participants will discuss "the greatest opportunities for research in the next few years" and "the greatest challenges to conducting CAM research" as well as whether they "see CAM research having an impact on trends in integrative medicine." People planning to attend the meeting on the NIH campus in Bethesda, Md., are asked to register by June 15...
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Compliance Corner: The 10 Best – And 10 Worst – Things You Can Do When FDA Inspects Your Firm (Part 10)
A panel of longtime industry experts offer manufacturers a list of things they should and shouldn’t do when an investigator from the US agency knocks on their facility door. In this tenth and final installment of a 10-part series, the experts explain why it’s important to be honest with investigators at all times.
It hasn’t even happened yet, but Brexit has already had a huge impact on the EU regulatory network and on the life science sector operating in the EU, particularly in the UK. We look back at some of the key events over the past ten years that have woven the UK ever more closely into the EU’s tight-knit regulatory network, and why the UK’s future links with that network will remain uncertain after the country leaves the EU on 31 January.